期刊文献+

Tat-聚乙二醇修饰明胶-硅氧烷纳米粒跨血脑屏障研究 被引量:3

Research on Tat Peptide-polyethylene Glycol Modified Gelatin-siloxane Nanoparticles Across the Blood-brain Barrier
原文传递
导出
摘要 明胶-硅氧烷杂化材料具有低毒、表面易修饰、易重复合成等优点,并可介导外源基因在细胞内进行高效率转染,是一种潜在的高效基因载体材料。本文通过两步溶胶-凝胶反应合成明胶-硅氧烷纳米粒(GS NPs),经Tat多肽(KYGRRRQRRKKRGC)、聚乙二醇(PEG)表面修饰构成Tat-PEG-GS NPs。应用透射电镜(TEM)、粒径仪和活体成像系统对其粒径、形貌、zeta电位、跨血脑屏障入脑能力进行评价。结果得出,Tat-PEG-GS NPs粒径分布在150~200nm、zeta电位(32.27±2.47)mV;TEM观察显示Tat-PEG-GS NPs可跨过血脑屏障到达脑组织,活体成像显示Tat-PEG-GS NPs较PEG-GS NPs在脑部的荧光强,Tat-PEG-GS NPs比PEG-GS NPs在肝脏、脾脏的荧光低,差异具有统计学意义。证明Tat-PEG-GS NPs可以逃逸内皮网状吞噬系统的吞噬,跨过血脑屏障到达脑实质内,是一种有潜力的入脑纳米载体系统。 Gelatin-siloxane nanoparticles (GS NPs) have been considered to be good gene carrier candidate in vitro, since they have several advantages such as low toxicity, easy preparation and surface modification. In this study, the Tat-PEG-GS NPs were synthesized by the gelatin-siloxane, surface-modified with the polyethylene glycol (H2N- PEG-COOH) and Tat peptide (KYGRRRQRRKKRGC) and thus constructed a delivery system which can cross BBB (Blood-brain barrier). The morphology, diameter, and zeta potential of Tat-PEG-GS NPs carrier system were characterized with transmission electron microscopy (TEM) and Nano-ZS zetasizer dynamic light scattering Detector. The organ distribution and dynamic evolution localized in the brain parenchyma of Tat-PEG-GS NPs in vivo was in- vestigated with Cri in vivo imaging system and TEM. The obtained Tat-PEG-GS NPs were approximately spherical in shape with average particle size of 150-200 nm and zeta potentials of (32.27±2.47) mV. In vivo imaging results showed that the accumulation of Tat-PEG-GS NPs was higher in the brain than the accumulation of PEG-GS NPs, but the accumulation of Tat-PEG-GS NPs was lower in the liver than the accumulation of PEG-GS NPs. These differences are statistically significant. The nanocomplex could cross the BBB and reach the neural tissues tested with TEM. The Tat-PEG-GS NPs could cross the BBB and escape the arrest of the reticuloendothelial system (RES), and it would be potential nano-carrier systems for central delivery.
出处 《生物医学工程学杂志》 CAS CSCD 北大核心 2012年第3期486-490,500,共6页 Journal of Biomedical Engineering
基金 福建省自然科学基金资助项目(2006J0188) 厦门市科技局基金资助项目(3502Z20064013)
关键词 细胞穿膜肽 纳米粒子 血脑屏障 体内实验 Cell-penetrating peptide Nanoparticles Blood-brain barrier In vivo experiments
  • 相关文献

参考文献9

  • 1RANGANATH S H. CHI-HWA W. Biodegradable microfibet imphmts delivering paelitaxel for post-surgical chemotherapy against malignant glioma [J]. Biomaterials, 2008, 29 (20): 2996-3003.
  • 2PEP, RIN R J, FAGAN A M, HOLTZMAN D M. Muhimodal techniques for diagnosis and prognosis of alzheimer's disease[J]. Nature, 2009, 461(7266): 916-922.
  • 3ROWE J B, HUGHES L, GHOSH B C, et al. Parkinson's disease and dopaminergie therapy--differential effects on movement,reward and cognition[J]. Brain, 2008, 131 ( Pt 8) : 2094-2105.
  • 4JONES A R, SHUSTA E V. Blood-brain barrier transport of therapeutics via reeeptor-mectiation[J]. Pharm Res, 2007, 24 (9) : 1759-1771.
  • 5TEIXIDO M, GIRALT E. The role of peptides in blood-brain barrier nanotechnology[J]. J Pept Sci, 2008, 14(2): 163-173.
  • 6PARDRIDGEW M. Crossing the blood-brain barrier:are we gettingit righl? [J]. Drug Discov Today, 2001, 6(1): 1-2.
  • 7PARDRIDGE W M. William pardridgc discusses the lack of BBB research, interview by rebecca N. lawrence[J]. Drug Discoy Today, 2002, 7(4): 22:3-226.
  • 8GARCIA-GARCIA E, ANDRIEUX K, GIL S, et al. Colloidal carriers and blood-brain barrier(BBB)translocation: a way to deliver drugs to the brain? [J].Int J Pharm, 2005, 298 (2), 274-292.
  • 9VERONESE F M, PEGYLATION P G. Successful approach to drug delivery[J].Drug Discov Today, 2005, 10 (21) : 1451-1458.

同被引文献41

  • 1朱役,贾绍昌,蔡凯,项方.靶向血管内皮生长因子的纳米颗粒制备及其对大肠癌细胞株SW620的作用[J].医学研究生学报,2011,24(10):19-22. 被引量:8
  • 2胡永祥,牛津梁,张文博,高林.聚乙二醇修饰药物技术的研究进展[J].中国生化药物杂志,2004,25(6):369-373. 被引量:12
  • 3施斌,方超,游美羡,裴元英.聚乙二醇修饰对羟喜树碱隐形纳米囊泡的肿瘤靶向和抑瘤作用的影响[J].中国临床药学杂志,2006,15(1):46-49. 被引量:15
  • 4Yu WY, Zhang N. Surface modification of nanocarriers for cancer therapy [ J ]. Curr Nanosci, 2009, 5 (2) : 123 - 134.
  • 5Li ZJ, Cho CH. Development of peptides as potential drugs for cancer therapy [ J]. Curr Pharm Design, 2010, 16 (10) : 1180 -1189.
  • 6Lee S, Xie J, Chen X. Peptide - based probes for targeted molecular imaging[ J ]. Biochemistry - US, 2010, 49 (7) : 1364 - 1376.
  • 7Li Z, Zhao R, Wu X, et al. Identification and character- ization of a novel peptide ligand ofepidermal growth factor receptor for targeted delivery of therapeutics [ J ]. FASEB J, 2005, 19 (14) : 1978 - 1985.
  • 8Rogers SJ, Harrington K J, Rhys -Evans P, et al. Biologi- cal significance of c - erbB family oncogenes in head and neck cancer[Jl. Cancer Metast Rev, 2005, 24(1 ) : 47 - 69.
  • 9Milane L, Duan ZF, Amiji M. Pharmacokinetics and bio- distribution of lonidamine/paclitaxel loaded, EGFR - tar- geted nanoparticles in an orthotopic animal model of multi - drug resistant breast cancer [ J ]. Nanomedicine - UK, 2011, 7(4) : 435 -444.
  • 10Milane L, Duan ZF, Amiji M. Development of EGFR - Targeted Polymer Blend Nanocarriers for Combination Pa- clitaxelfLonidamine Delivery To Treat Multi - Drug Re- sistance in Human Breast and Ovarian Tumor Cells [ J ]. Mol Pharm, 2010, 8(1): 185 -203.

引证文献3

二级引证文献8

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部